According to a newspaper report, the US pharmaceutical company Merck & Co wants to take over the cancer drug specialist Revolution Medicines.
The “Financial Times” (“FT”) reported on Thursday evening that the purchase price was between $28 and $32 billion, citing people familiar with the matter. An agreement could still take weeks, it said. Other large pharmaceutical companies also have their eye on revolution. According to the information, Revolution Medicines is researching drugs against pancreatic cancer, one of the deadliest forms of cancer. Shares of Revolution Medicines gained 4.6 percent in regular NASDAQ trading and rose another 15.34 percent to $123.86 in after-hours trading. Merck & Co. shares rose 2.2 percent at the close of trading on the NYSE on Thursday. After hours, however, it fell by 0.35 percent to 110.61 US dollars.
/men
LONDON (dpa-AFX)
By the way: Merck and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leverage products on Merck
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Merck
The leverage must be between 2 and 20
Advertising
